Monthly weight-loss shots on the horizon! Learn about new drugs like MariTide and why Black participation in clinical trials ...

(Reuters) -Amgen's long-acting experimental obesity drug MariTide needs to be given at a low starting dose to limit side effects like vomiting, according to mid-stage trial results presented at a ...

Amgen stock rose 13% as obesity drug MariTide advances. Click here to find out why AMGN stock is a Buy.

Amgen's weight-loss drug MariTide had a successful Phase 2 trial so the company is expanding development plans to study its use for heart disease and sleep apnea.

Eli Lilly and Novo Nordisk, which already have approved GLP-1 weight loss drugs that are raking in billions of revenues, have ...

This year, drug companies have been living under a cloud of uncertainty created by the Trump administration. Threats of tough ...

Amgen Inc. (NASDAQ:AMGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. On June 23, the company ...

MariTide helped participants lose up to 20% of their body weight in a year-long trial. But it could be years before the new ...

--Amgen today announced full results from Part 1 of the Phase 2 study for MariTide in patients living with obesity, with and without Type 2 diabetes, will be presented along with new data from the ...

At the diabetes conference, Eli Lilly presented results of a phase 1 trial of its experimental drug, eloralintide. Unlike GLP-1 drugs, it targets a hormone that slows stomach emptying. Over 12 weeks, ...

Amgen shares are trading lower Monday afternoon. The company released full results from part one of its phase two study of MariTide.

Amgen is expanding development plans for its weight-loss drug MariTide to study its use for heart disease and sleep apnea. In a phase 2 trial, the drug demonstrated 20% average weight loss among ...